Physician profile
Jay B Wish
NPI 1851311922
$501,673.28
in general payments reported to CMS, 2019-2025
26 companies · $92K in 2025
The $92K reported for 2025 was more than what 99% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144K · 2020: $59K · 2021: $52K · 2022: $26K · 2023: $82K · 2024: $47K · 2025: $92K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $79K · Consulting Fee: $66K · Honoraria: $39K · Travel and Lodging: $30K · Food and Beverage: $6,787 · Education: $18.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $78,639.00 |
| Consulting Fee | $65,963.50 |
| Honoraria | $38,850.00 |
| Travel and Lodging | $30,482.00 |
| Food and Beverage | $6,786.95 |
| Education | $18.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $130,194.24 | 2019-2025 | Vafseo, Auryxia |
| Glaxosmithkline, LLC. | $120,636.10 | 2022-2024 | Jesduvroq, Benlysta |
| Astrazeneca Pharmaceuticals Lp | $98,088.04 | 2019-2021 | |
| Calliditas Therapeutics US INC. | $56,635.47 | 2024-2025 | Tarpeyo |
| Rockwell Medical, INC. | $26,614.30 | 2019-2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $19,841.62 | 2019-2024 | |
| Vifor Fresenius Medical Care Renal Pharma Ltd. | $15,011.50 | 2019-2020 | |
| Ardelyx, INC. | $6,460.57 | 2022-2025 | Xphozah 30 Mg, Ibsrela |
| Vifor (International) Ltd. | $5,463.50 | 2024 | |
| Csl Behring | $5,124.00 | 2021-2025 | |
| Astrazeneca Uk Limited | $5,000.00 | 2022-2023 | |
| Amgen INC. | $4,838.08 | 2019-2023 | Aranesp, Parsabiv, Tavneos |
| Vifor Pharma, INC. | $3,049.92 | 2019-2022 | |
| Fresenius USA Marketing, INC. | $1,337.75 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $1,040.00 | 2019-2024 | Jynarque |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $797.65 | 2023-2025 | |
| Pfizer INC. | $780.00 | 2019 | |
| American Regent | $300.07 | 2019-2024 | Injectafer |
| Apellis Pharmaceuticals, INC. | $104.19 | 2025 | Empaveli |
| Mallinckrodt Hospital Products INC. | $87.88 | 2025 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $60.07 | 2021 | |
| Mallinckrodt Enterprises LLC | $55.82 | 2019 | |
| Travere Therapeutics, INC. | $51.00 | 2019 | |
| Corcept Therapeutics | $48.95 | 2024 | Korlym |
| Quanta Dialysis Technologies INC | $26.61 | 2022 | |
| Ani Pharmaceuticals, INC. | $25.95 | 2024 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Wish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.